|Bid||2.8100 x 1800|
|Ask||3.3600 x 800|
|Day's Range||3.0400 - 3.2150|
|52 Week Range||2.3400 - 9.0000|
|Beta (3Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Bay Area companies are gearing up for ASCO, HCP's Brisbane biotech building is on the rise and more in our Health Care Digest.
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host and webcast an investor event on Monday, June 3, 2019 at 6:30 am CDT in Chicago, IL. Guest speaker, Dr. Funda Meric-Bernstam of MD Anderson Cancer Center, is a principal investigator for the Phase 1 study of STING pathway activator ADU-S100 (MIW815) in combination with spartalizumab (PDR001), Novartis’ investigational anti-PD-1 monoclonal antibody, in patients with advanced/metastatic solid tumors or lymphomas.
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided an update on its clinical development programs for BION-1301, a first-in-class humanized IgG4 monoclonal antibody that fully blocks APRIL binding to both the BCMA and TACI receptors.
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -70.59% and -51.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
BERKELEY, Calif., May 07, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.
During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.
During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.
Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.
For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.
WellCare Health's (WCG) first-quarter earnings are likely to gain from a rise in membership, partly offset by high debt load.
On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.